WHO makes new executive board appointments

The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.

The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.